

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



#1636

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: U.S. Patent & Trademark Office, P.O. Box 2327, Arlington, VA 22202

Marcia Rossell
Type or print name

Marcia Rossell
Signature

April 7, 2003
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Confirmation No. 4496

CHENG, ET AL.

Art Unit: 1636

APPLICATION NO: 10/081,969

Examiner: Marvich, Maria

FILED: FEBRUARY 22, 2002

Atty. Docket: 4-31704A

FOR: NOVEL ONCOLYTIC ADENOVIRAL VECTORS

U.S. Patent & Trademark Office
P.O. Box 2327
Arlington, Virginia 22202

RECEIVED
APR 14 2003
TECH CENTER 1600/2900

TRANSMITTAL LETTER

Sir:

Enclosed please find the following:

- a. Information Disclosure Statement (1 page);
- b. PTO Form 1449 (20 pages) with cited references;
- c. Fee Letter for Information Disclosure Statement;
- d. Fee Transmittal Sheet; and
- e. Return postcard.


Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Bldg. 430
East Hanover, NJ 07936-1080
(301) 258-4832

Douglas Golightly

Douglas Golightly
Patent Agent
Reg. No. 51,244

Date: April 7, 2003



FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180

Complete if Known

Application Number	10/081,969
Filing Date	February 22, 2002
First Named Inventor	Cheng
Examiner Name	Marvich, Maria
Art Unit	1636
Attorney Docket No.	4-31704A

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number
Deposit Account Name

19-0134

Novartis Corporation

The Commissioner is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☐ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 750	2001 375	Utility filing fee	
1002 330	2002 165	Design filing fee	
1003 520	2003 260	Plant filing fee	
1004 750	2004 375	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	

SUBTOTAL (1) (\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	-20** =	X	
Multiple Dependent Claims	-3** =	X	

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 84	2201 42	Independent claims in excess of 3
1203 280	2203 140	Multiple dependent claim, if not paid
1204 84	2204 42	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for <i>ex parte</i> reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 410	2252 205	Extension for reply within second month	
1253 930	2253 465	Extension for reply within third month	
1254 1,450	2254 725	Extension for reply within fourth month	
1255 1,970	2255 985	Extension for reply within fifth month	
1401 320	2401 160	Notice of Appeal	
1402 320	2402 160	Filing a brief in support of an appeal	
1403 280	2403 140	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,300	2453 650	Petition to revive - unintentional	
1501 1,300	2501 650	Utility issue fee (or reissue)	
1502 470	2502 235	Design issue fee	
1503 630	2503 315	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	180
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 750	2809 375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 750	2810 375	For each additional invention to be examined (37 CFR 1.129(b))	
1801 750	2801 375	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 180

SUBMITTED BY

(Complete if applicable)

Name (Print/Type)	Douglas Golightly	Registration No. (Attorney/Agent)	51,244	Telephone	301-258-4832
Signature		Date	April 7, 2003		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

CHENG, ET AL.

APPLICATION NO: 10/081,969

FILED: FEBRUARY 22, 2002

FOR: NOVEL ONCOLYTIC ADENOVIRAL VECTORS

Confirmation No. 4496

Art Unit: 1636

Examiner: Marvich, Maria

Atty. Docket: 4-31704A

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

INFORMATION DISCLOSURE STATEMENT

RECEIVED
APR 14 2003
TECH CENTER 1600/2900

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449. Copies of these references are enclosed herewith.


The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

04/11/2003 HMEKONEN 00000054 190134 10081969

01 FC:1806 180.00 CH

Novartis
Corporate Intellectual Property
One Health Plaza, Bldg. 430
East Hanover, NJ 07936-1080
(301) 258-4832


Douglas Golightly
Patent Agent
Reg. No. 51,244

Date: April 7, 2003



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

CHENG, ET AL.

APPLICATION NO: 10/081,969

FILED: FEBRUARY 22, 2002

FOR: NOVEL ONCOLYTIC ADENOVIRAL VECTORS

Confirmation No. 4496

Art Unit: 1636

Examiner: Marvich, Maria

Atty. Docket: 4-31704A

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

TECH CENTER 1600/2900

APR 14 2003

RECEIVED


FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c). The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Bldg. 430
East Hanover, NJ 07936-1080
(301) 258-4832


Douglas Golightly
Patent Agent
Reg. No. 51,244

Date: April 7, 2003

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
Ennist, et al.
FILING DATE
FEBRUARY 22, 2002

Group



(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	10/081,961	2/22/02	Gorziglia, et al.			
	AB	2001/0006633A1	7/5/01	Kirn, D.			
	AC	5,672,344	9/30/97	Kelley, et al.			
	AD	5,677,178	10/14/97	McCormick, F.			
	AE	5,698,443	12/16/97	Henderson, et al.			
	AF	5,707,618	1/13/98	Armentano, et al.			
	AG	5,830,686	11/3/98	Henderon, D.			
	AH	5,837,511	11/17/98	Falck-Pederson, et al.			
	AI	5,871,726	2/16/99	Henderson, et al.			
	AJ	5,994,128	11/30/99	Fallaux, et al.			
	AK	5,998,205	12/7/99	Hellenbeck, et al.			
	AL	6,057,299	5/2/00	Henderson, D.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM	WO 00/03029	1/20/00	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 00/15820	3/23/00	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 00/22124	4/20/00	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 00/29599	5/25/00	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	WO 00/31286	6/2/00	WIPO			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Adams, et al., "Transcriptional Control by E2F," <i>Seminars in Cancer Biology</i> , 6:99-108 (1995)
	AS	Albert, et al., "Dendritic Cells Acquire Antigen From Apoptotic Cells and Induce Class I-restricted CTLs," <i>Nature</i> , 392:86-89 (March 1998)
	AT	Aleman, et al., "Replicative Adenoviruses for Cancer Therapy," <i>Nature Biotechnology</i> , 18:723-727 (July 2000)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
Ennist, et al.
FILING DATE
FEBRUARY 22, 2002

Group

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	6,136,792	10/24/00	Henderson, D.			
	AB	6,197,293 B1	3/6/01	Henderson, et al.			
	AC	6,254,862 B1	7/3/01	Little, et al.			
	AD	6,271,207 B1	8/7/01	Cristiano, et al.			
	AE	6,297,219 B1	10/2/01	Nabel, et al.			
	AF	6,432,700 B1	8/13/02	Henderson, et al.			
	AG	6,436,394 B1	8/20/02	Henderson, et al.			
	AH	6,495,130 B1	12/17/02	Henderson, et al.			
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM	WO 00/39319 ✓	7/6/00	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 00/46355 ✓	8/10/00	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 00/47768 ✓	8/17/00	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 00/56909 ✓	9/28/00	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	WO 00/67576 -	11/16/00	WIPO			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	✓ AR	Altmann, et al., "Epothilones and Related Structures -- a New Class of Microtubule Inhibitors with Potent In Vivo Antitumor Activity," <i>Biochemica et Biophysica Acta</i> , 1470:M79-M91 (2000)
	AS	Angelichio, et al., "Comparison of Several Promoters and Polyadenylation Signals for Use in Heterologous Gene Expression in Cultured Drosophila Cells," <i>Nucleic Acids Research</i> , 19(18):5037-5043 (1991)
	AT	Armitage, J., "Emerging Applications of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," <i>Blood</i> , 92(12):4491-4508 (December 15, 1998)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.


FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
Ennist, et al.
FILING DATE
FEBRUARY 22, 2002

Group



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 00/70071 ✓	11/23/00	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 01/02540 ✓	1/11/01	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 01/04282 ✓	1/18/01	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 01/04334 ✓	1/18/01	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	WO 01/23004 ✓	4/5/01	WIPO			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Armstrong, et al., "Antitumor Effects of Granulocyte-Macrophage Colony-Stimulating Factor Production by Melanoma Cells," <i>Cancer Research</i> , 56:2191-2198 (May 1, 1996)
	AS	Axelrod, et al., "A Novel Oncolytic Adenovirus Encoding an IL-6/sIL-6R Fusion Protein," Abstract No. P6, presented at <i>The 10th Annual Meeting of the European Society for Gene Therapy</i> , Antibes, France, October 13-16, 2002
	AT	Babiss, et al., "Cellular Promoters Incorporated into the Adenovirus Genome: Effects of Viral Regulatory Elements on Transcription Rates and Cell Specificity of Albumin and β -Globin Promoters," <i>Molecular and Cellular Biology</i> , 6(11):3798-3806 (November 1986)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

4-31704A

APPLICATION NO.

10/081,969

APPLICANT

Ennist, et al.


FILING DATE

FEBRUARY 22, 2002

Group

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM	WO 01/36650 ✓	5/25/01	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 01/72341	10/4/01	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 01/73093	10/4/01	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 02/068627	9/6/02	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	WO 94/18992	9/1/94	WIPO			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Benedict, et al., "Three Adenovirus E3 Proteins Cooperate to Evade Apoptosis by Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptor-1 and -2," <i>The Journal of Biological Chemistry</i> , 276(5):3270-3278 (February 2, 2001)
	AS	Bergsland, et al., "Shedding Old Paradigms: Developing Viruses to Treat Cancer," <i>Journal of Clinical Oncology</i> , 20(9):2220-2222 (May 1, 2002)
	AT	Bert, et al., "Generation of an Improved Luciferase Reporter Gene Plasmid That Employs a Novel Mechanism for High-Copy Replication," <i>Plasmid</i> , 44:173-182 (September 2000)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
Ennist, et al.
FILING DATE
FEBRUARY 22, 2002

Group



(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 95/19434	7/20/95	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 96/34969	11/7/96	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 97/01358	1/16/97	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 97/04805	2/13/97	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	WO 97/48277	12/24/97	WIPO			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Black, et al., "Regulation of E2F: A Family of Transcription Factors Involved in Proliferation Control," <i>Gene</i> , 237:281-302 (1999)
	AS	Boon, et al., "Cancer Tumor Antigens," <i>Current Opinion in Immunology</i> , 9:681-683 (1997)
	AT	Bouvet, et al., "Suppression of the Immune Response to an Adenovirus Vector and Enhancement of Intratumoral Transgene Expression by Low-Dose Etoposide," <i>Gene Therapy</i> , 5:189-195 (1998)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
Ennist, et al.
FILING DATE
FEBRUARY 22, 2002

Group



(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 98/13508	4/2/98	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 98/27207	6/25/98	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 98/28469	7/2/98	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 98/35028	8/13/98	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	WO 98/39464	9/11/98	WIPO			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Bristol, et al., "GM-CSF Containing Oncolytic Adenoviruses for the Treatment of Cancer," Abstract No. P2, presented at <i>The 10th Annual Meeting of the European Society for Gene Therapy</i> , Antibes, France, October 13-16, 2002
	AS	Bristol, et al., "GM-CSF Containing Oncolytic Adenoviruses for the Treatment of Cancer," poster presented at <i>The 10th Annual Meeting of the European Society of Gene Therapy</i> , Antibes, France, October 13-16, 2002
	AT	Bristol, et al., "GM-CSF Mediated Stimulation of Innate Anti-tumor Responses," poster presented at the <i>Keystone Symposia, Basic Aspects of Tumor Immunology</i> , February 17-23, 2003

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
Ennist, et al.
FILING DATE
FEBRUARY 22, 2002

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 98/39465	9/11/98	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 98/39466	9/11/98	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 98/39467	9/11/98	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 99/06576	2/11/99	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	WO 99/28469	6/10/99	WIPO			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Bristol, et al., "In Vivo Anti-Tumor Activity of Oncolytic Adenoviruses that Express GM-CSF in Xenograft Tumor Models," <i>American Society for Gene Therapy, 5th Annual Meeting</i> , June 5-9, 2002; poster presented June 6, 2002
	AS	Bristol, et al., "In Vivo Anti-Tumor Activity of Oncolytic Adenoviruses that Express GM-CSF in Xenograft Tumor Models," <i>Molecular Therapy</i> , 5(5):abstract No. 311 (May 2002)
	AT	Bruder, et al., "Nuclear Factor EF-1A Binds to the Adenovirus E1A Core Enhancer Element and to Other Transcriptional Control Regions," <i>Molecular and Cellular Biology</i> , 9(11):5143-5153 (November 1989)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
Ennist, et al.
FILING DATE
FEBRUARY 22, 2002

Group



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 99/55831	11/4/99	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 99/59604	11/25/99	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 92/03563	3/5/92	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Bryan, et al., "Evidence for an Alternative Mechanism for Maintaining Telomere Length in Human Tumors and Tumor-derived Cell Lines," <i>Nature Medicine</i> , 3(11):1271-1274 (November 1997)
	AS	Chang, et al., "Immunogenetic Therapy of Human Melanoma Utilizing Autologous Tumor Cells Transduced to Secrete Granulocyte-Macrophage Colony-Stimulating Factor," <i>Human Gene Therapy</i> , 11:839-850 (April 10, 2000)
	AT	Chao, et al., "Assembly of the Cleavage and Polyadenylation Apparatus Requires About 10 Seconds In Vivo and Is Faster for Strong Than for Weak Poly(A) Sites," <i>Molecular and Cellular Biology</i> , 19(8):5588-5600 (August 1999)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
Ennist, et al.
FILING DATE
FEBRUARY 22, 2002

Group



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Chen, et al., "Antiangiogenic Gene Therapy for Cancer via Systemic Administration of Adenoviral Vectors Expressing Secretable Endostatin," <i>Human Gene Therapy</i> , 11:1983-1996 (September 20, 2000)
AB	Chen, et al., "Cleavage Site Determinants in the Mammalian Polyadenylation Signal," <i>Nucleic Acids Research</i> , 23(14):2614-2620 (1995)
AC	Chia, et al., "A Novel Conditionally Oncolytic Adenovirus for the Treatment of Nasopharyngeal Carcinoma (NPC)," <i>Proceedings of the American Association for Cancer Research</i> , 43:1098-1099, abstract No. 5441 (March 2002)
AD	Chiocca, E., "Oncolytic Viruses," <i>Nature</i> , 2:938-950 (December 2002)
AE	Christ, et al., "Modulation of the Inflammatory Properties and Hepatotoxicity of Recombinant Adenovirus Vectors by the Viral E4 Gene Products," <i>Human Gene Therapy</i> , 11:415-427 (February 10, 2000)
AF	Colgan, et al., "Mechanism and Regulation of mRNA Polyadenylation," <i>Genes and Development</i> , 11:2755-2766 (1997)
AG	Curiel, et al., "Strategies to Improve the Therapeutic Utility of Conditionally Replicative Adenoviruses (CRAds) for Cancer Therapy," <i>Proceedings of the American Association for Cancer Research</i> , 43:662, abstract No. 3287 (March 2002)
AH	Demers, et al., "Antitumor Efficacy and Replication of an Oncolytic Adenovirus, 01/PEME, in Tumor Tissue Following Intravenous Administration," <i>Proceedings of the American Association for Cancer Research</i> , 43:663, abstract No. 3291 (March 2002)
AI	Denome, et al., "Patterns of Polyadenylation Site Selection in Gene Constructs Containing Multiple Polyadenylation Signals," <i>Molecular and Cellular Biology</i> , 8(11):4829-4839 (November 1988)
AJ	DeWeese, et al., "A Phase I Trial of CV706, a Replication-Competent, PSA Selective Oncolytic Adenovirus, for the Treatment of Locally Recurrent Prostate Cancer Following Radiation Therapy," <i>Cancer Research</i> , 61:7464-7472 (October 15, 2001)
AK	Dong, et al., "Angiostatin-Mediated Suppression of Cancer Metastases by Primary Neoplasms Engineered to Produce Granulocyte/Macrophage Colony-Stimulating Factor," <i>J. Exp. Med.</i> , 188(4):755-763 (August 17, 1998)
AL	Dong, et al., "Macrophage-Derived Metalloelastase is Responsible for the Generation of Angiostatin in Lewis Lung Carcinoma," <i>Cell</i> , 88:801-810 (March 21, 1997)
AM	Doronin, et al., "Tissue-Specific, Tumor-Selective, Replication-Competent Adenovirus Vector for Cancer Gene Therapy," <i>Journal of Virology</i> , 75(7):3314-3324 (April 2001)
AN	Doronin, et al., "Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein," <i>Journal of Virology</i> , 74(13):6147-6155 (July 2000)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.


FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
Ennist, et al.
FILING DATE
FEBRUARY 22, 2002

Group



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Dranoff, et al., "Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity," <i>Proc. Natl. Acad. Sci. USA</i> , 90:3539-3543 (April 1993)
AB	Duque, et al., "Adenovirus Lacking the 19-kDa and 55-kDa E1B Genes Exerts a Marked Cytotoxic Effect in Human Malignant Cells," <i>Cancer Gene Therapy</i> , 6(6):554-563 (1999)
AC	Dyson, N., "The Regulation of E2F by pRB-family Proteins," <i>Genes and Development</i> , 12:2245-2262 (August 1998)
AD	Emens, et al., "Chemotherapy: Friend or Foe to Cancer Vaccines?" Current Opinion in <i>Molecular Therapeutics</i> , 3(1):77-84 (February 2001)
AE	Emery, et al., "A Chromatin Insulator Protects Retrovirus Vectors from Chromosomal Position Effects," <i>Proc. Natl. Acad. Sci. USA</i> , 97(16):9150-9155 (August 1, 2000)
AF	Ennist, D., "Oncolytic Adenoviruses Containing GM-CSF for the Treatment of Cancer," oral presentation at the 4th International Conference, The Adjuvant Therapy of Malignant Melanoma, March 15-16, 2002
AG	Ennist, D., "Oncolytic Adenoviruses Containing GM-CSF for the Treatment of Cancer," abstract presented at the 4th International Conference, The Adjuvant Therapy of Malignant Melanoma, March 15-16, 2002
AH	Ennist, et al., "Oncolytic Adenoviruses Containing GM-CSF for the Treatment of Cancer," <i>Proceedings of the American Association for Cancer Research</i> , 43:1098, abstract No. 5437 (March 2002)
AI	Ennist, et al., "Oncolytic Adenoviruses Containing GM-CSF for the Treatment of Cancer," oral presentation at the 93rd Annual Meeting of the American Association for Cancer Research, April 6-10, 2002, San Francisco, California
AJ	Fallaux, et al., "New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent Adenoviruses," <i>Human Gene Therapy</i> , 9:1909-1917 (September 1, 1998)
AK	Fan, et al., "Efficient Gene Delivery into Human Primary Glioma Cells by Fiber Retargeted Adenoviral Vectors: Implications for In Vivo Gene Delivery into Malignant Gliomas," Abstract No. P7, presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002
AL	Fang, et al., "Diminishing Adenovirus Gene Expression and Viral Replication by Promoter Replacement," <i>Journal of Virology</i> , 71(6):4798-4803 (June 1997)
AM	Flomenberg, et al., "Molecular Epidemiology of Adenovirus Type 35 Infections in Immunocompromised Hosts," <i>The Journal of Infectious Diseases</i> , 15(6):1127-1134 (June 1987)
AN	Flomenberg, et al., "Sequence and Genetic Organization of Adenovirus Type 35 Early Region 3," <i>Journal of Virology</i> , 62(11):4431-4437 (November 1988)

EXAMINER

DATE CONSIDERED


*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
Ennist, et al.
FILING DATE
FEBRUARY 22, 2002

Group



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Fridovich-Keil, et al., "Improved Expression Vectors for Eukaryotic Promoters-Enhancer Studies," <i>BioTechniques</i> , 11(5):572-579 (1991)
AB	Fujiwara, et al., "Safety and Clinical Efficacy of Adenoviral p53 Gene Therapy for Non-small Cell Lung Cancer: Potent Application as Tumor Dormancy Therapy," <i>Proceedings of the American Association for Cancer Research</i> , 43:663, abstract No. 3290 (March 2002)
AC	Ganly, et al., "A Phase I Study of Onyx-015, an E1B Attenuated Adenovirus, Administered Intratumorally to Patients with Recurrent Head and Neck Cancer," <i>Clinical Cancer Research</i> , 6:798-806 (March 2000)
AD	Gil, et al., "Position-Dependent Sequence Elements Downstream of AAUAAA Are Required for Efficient Rabbit α -Globin mRNA 3' End Formation," <i>Cell</i> , 49:399-406 (May 8, 1987)
AE	Gope, et al., "Abundance and State of Phosphorylation of the Retinoblastoma Susceptibility Gene Product in Human Colon Cancer," <i>Molecular and Cellular Biochemistry</i> , 110:123-133 (1992)
AF	Gu, et al., "Tumor-Specific Transgene Expression from the Human Telomerase Reverse Transcriptase Promoter Enables Targeting of the Therapeutic Effects of the Bax Gene to Cancers," <i>Cancer Research</i> , 60:5359-5364 (October 1, 2000)
AG	Habib, et al., "E1B-Deleted Adenovirus (dl1520) Gene Therapy for Patients with Primary and Secondary Liver Tumors," <i>Human Gene Therapy</i> , 12:219-226 (February 10, 2001)
AH	Hallenbeck, et al., "A Novel Tumor-Specific Replication-Restricted Adenoviral Vector for Gene Therapy of Hepatocellular Carcinoma," <i>Human Gene Therapy</i> , 10:1721-1733 (July 1, 1999)
AI	Hallenbeck, et al., "Oncolytic Adenoviruses Dependent Upon Two Prevalent Alterations in Human Cancer; Disregulation of the RB-Pathway and Telomerase," <i>American Society of Gene Therapy 5th Annual Meeting</i> , June 5-9, 2002, poster presented on June 5, 2002
AJ	Hallenbeck, et al., "Oncolytic Adenoviruses Dependent Upon Two Prevalent Alterations in Human Cancer; Disregulation of the RB-Pathway and Telomerase," <i>Molecular Therapy</i> , 5(5):Abstract 165 (May 2002)
AK	Hallenbeck, P., "Oncolytic Adenoviruses Dependent Upon Two Prevalent Alterations in Human Cancer; Disregulation of the Rb-Pathway and Telomerase," oral presentation presented at the <i>3rd International Symposium on Genetic Anticancer Agents</i> , Amsterdam, The Netherlands, March 1-2, 2002
AL	Hans, et al., "Functionally Significant Secondary Structure of the Simian Virus 40 Late Polyadenylation Signal," <i>Molecular and Cellular Biology</i> , 20(8):2926-2932 (April 2000)
AM	Hatfield, et al., "Redundant Elements in the Adenovirus Type 5 Inverted Terminal Repeat Promote Bidirectional Transcription <i>In Vitro</i> and Are Important for Virus Growth <i>In Vivo</i> ," <i>Virology</i> , 184:265-276 (1991)
AN	Hatfield, et al., "The NFIII/OCT-1 Binding Site Stimulates Adenovirus DNA Replication <i>In Vivo</i> and Is Functionally Redundant with Adjacent Sequences," <i>Journal of Virology</i> , 67(7):3931-3939 (July 1993)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
Ennist, et al.
FILING DATE
FEBRUARY 22, 2002

Group



(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Hay, C., "Oncolytic Adenovirus Dependent Upon Two Prevalent Alterations in Human Cancer," <i>The 10th Annual Meeting of the European Society of Gene Therapy</i> , Antibes, France, October 13-16, 2002, oral presentation presented on October 16, 2002
AB	Hearing, et al., "The Adenovirus Type 5 E1A Transcriptional Control Region Contains a Duplicated Enhancer Element," <i>Cell</i> , 33:695-703 (1983)
AC	Heise, et al., "Efficacy of a Replication-Competent Adenovirus (ONYX-015) Following Intratumoral Injection: Intratumoral Spread and Distribution Effects," <i>Cancer Gene Therapy</i> , 6(6):499-504 (1999)
AD	Heise, et al., "Efficacy with a Replication-Selective Adenovirus Plus Cisplatin-Based Chemotherapy: Dependence on Sequencing but not p53 Functional Status or Route of Administration," <i>Clinical Cancer Research</i> , 6:4908-4914 (December 2000)
AE	Heise, et al., "ONYX-015, an E1B Gene-attenuated Adenovirus, Causes Tumor-specific Cytolysis and Antitumoral Efficacy that can be Augmented by Standard Chemotherapeutic Agents," <i>Nature Medicine</i> , 3(6):639-645 (June 1997)
AF	Heise, et al., "Replication-Selective Adenoviruses as Oncolytic Agents," <i>The Journal of Clinical Investigation</i> , 105(7):847-851 (April 2000)
AG	Hermiston, T., "Gene Delivery From Replication-Selective Viruses: Arming Guided Missiles in the War Against Cancer," <i>The Journal of Clinical Investigation</i> , 105(9):1169-1172 (May 2000)
AH	Hiyama, et al., "Telomerase Activity in Small-Cell and Non-Small-Cell Lung Cancers," <i>Journal of the National Cancer Institute</i> , 87(12):895-902 (June 21, 1995)
AI	Horikawa, et al., "Cloning and Characterization of the Promoter Region of Human Telomerase Reverse Transcriptase Gene," <i>Cancer Research</i> , 59:826-830 (February 15, 1999)
AJ	Horwitz, M., "Adenovirus Immunoregulatory Genes and Their Cellular Targets," <i>Virology</i> , 279:1-8 (January 5, 2001)
AK	Hurford, et al., "pRB and p107/p130 are Required for the Regulated Expression of Different Sets of E2F Responsive Genes," <i>Genes & Development</i> , 11:1447-1463 (1997)
AL	Hwang, et al., "Polyadenylation of Vesicular Stomatitis Virus mRNA Dictates Efficient Transcription Termination at the Intercistronic Gene Junctions," <i>Journal of Virology</i> , 72(3):1805-1813 (March 1998)
AM	Ilan, et al., "Insertion of the Adenoviral E3 Region into a Recombinant Viral Vector Prevents Antiviral Humoral and Cellular Immune Responses and Permits Long-Term Gene Expression," <i>Proc. Natl. Acad. Sci. USA</i> , 94:2587-2592 (March 1997)
AN	International Search Report for PCT/US02/05300, March 5, 2003

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.


FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
Ennist, et al.
FILING DATE
FEBRUARY 22, 2002

Group



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Jaffee, et al., "Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation," <i>Journal of Clinical Oncology</i> , 19(1):145-156 (January 1, 2001)
AB	Jaffee, et al., "Use of Murine Models of Cytokine-Secreting Tumor Vaccines to Study Feasibility and Toxicity Issues Critical to Designing Clinical Trials," <i>Journal of Immunotherapy</i> , 18(1):1-9 (1995)
AC	Jakubczak, et al., "Construction and Characterization of Oncolytic Adenoviruses," <i>Molecular Therapy</i> , 3(5):Abstract 442 (May 2001)
AD	Jakubczak, et al., "Construction and Characterization of Oncolytic Adenoviruses," <i>The Fourth Annual Meeting of the American Society of Gene Therapy</i> , May 30-June 3, 2001; poster presented on June 1, 2001
AE	Jakubczak, et al., "Evaluation of In Vivo Selectivity of Oncolytic Adenoviruses Following Intravenous Administration in SCID Mice Using Toxicological and Molecular Parameters," <i>American Society of Gene Therapy, 5th Annual Meeting</i> , June 5-9, 2002; poster presented June 7, 2002
AF	Jakubczak, et al., "Evaluation of In Vivo Selectivity of Oncolytic Adenoviruses Following Intravenous Administration in SCID Mice Using Toxicological and Molecular Parameters," <i>Molecular Therapy</i> , 5(5):abstract No. 851 (March 2002)
AG	Jakubczak, J., "An Oncolytic Adenovirus Dependent Upon Two Prevalent Alterations in Human Cancer; Disregulation of the Rb-Pathway and Telomerase," oral presentation presented at the <i>US-Japan Cooperative Cancer Research Program, Telomeres and Telomerase in Cancer Research</i> , Maui, HI, August 3-5, 2002
AH	Johnson, et al., "Autoregulatory Control of E2F1 Expression in Response to Positive and Negative Regulators of Cell Cycle Progression," <i>Genes and Development</i> , 8:1514-1525 (1994)
AI	Johnson, et al., "Cytosine Deaminase-armed Selectively Replicating Adenovirus for the Treatment of Cancer," <i>Proceedings of the American Association for Cancer Research</i> , 43:656, abstract No. 3257 (March 2002)
AJ	Johnson, et al., "Selectively Replicating Adenoviruses Targeting Deregulated E2F Activity are Potent, Systemic Antitumor Agents," <i>Cancer Cell</i> , 1:325-337 (May 2002)
AK	Kaelin, et al., "Expression Cloning of a cDNA Encoding a Retinoblastoma-Binding Protein with E2F-like Properties," <i>Cell</i> , 70:351-364 (July 24, 1992)
AL	Kessler, et al., "Requirement of A-A-U-A-A and Adjacent Downstream Sequences for SV40 Early Polyadenylation," <i>Nucleic Acids Research</i> , 14(12):4939-4953 (1986)
AM	Khuri, et al., "A Controlled Trial of Intratumoral ONYX-015, a Selectively-replicating Adenovirus, in Combination with Cisplatin and 5-fluorouracil in Patients with Recurrent Head and Neck Cancer," <i>Nature Medicine</i> , 6(8):879-885 (August 2000)
AN	Kilian, et al., "Isolation of a Candidate Human Telomerase Catalytic Subunit Gene, Which Reveals Complex Splicing Patterns in Different Cell Types," <i>Human Molecular Genetics</i> , 6(12):2011-2019 (1997)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)


 ATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
Ennist, et al.
FILING DATE
FEBRUARY 22, 2002

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Kim, et al., "Specific Association of Human Telomerase Activity with Immortal Cells and Cancer," <i>Science</i> , 266:2011-2015 (December 23, 1994)
AB	Kirn, D., "Clinical Research Results with dl1520 (Onyx-015), a Replication-selective Adenovirus for the Treatment of Cancer: What Have We Learned?" <i>Gene Therapy</i> , 8:89-98 (January 2001)
AC	Kirn, D., "Replication-selective Microbiological Agents: Fighting Cancer With Targeted Germ Warfare," <i>The Journal of Clinical Investigation</i> , 105(7):837-839 (April 2000)
AD	Kirn, D., "Replication-selective Oncolytic Adenoviruses: Virotherapy Aimed at Genetic Targets in Cancer," <i>Oncogene</i> , 19:6660-6669 (December 27, 2000)
AE	Kirn, D., "Virotherapy for Cancer: Current Status, Hurdles, and Future Directions," <i>Cancer Gene Therapy</i> , 9:959-960 (December 2002)
AF	Kirn, et al., "ONYX-015: Clinical Data are Encouraging," <i>Nature Medicine</i> , 4(12):1341-1342 (December 1998)
AG	Kirschweiger, G., "Genetic Therapies, Inc.: Tight-Lipped for Now," <i>Molecular Therapy</i> , 7(3):293 (March 2003)
AH	Kiyono, et al., "Both Rb/p16INK4a Inactivation and Telomerase Activity are Required to Immortalize Human Epithelial Cells," <i>Nature</i> , 396:84-88 (November 5, 1998)
AI	Kovesdi, et al., "Identification of a Cellular Transcription Factor Involved in E1A Trans-Activation," <i>Cell</i> , 45:219-228 (April 25, 1986)
AJ	Krajcsi, et al., "The Adenovirus E3-14.7K Protein and the E3-10.4K/14.5K Complex of Proteins, Which Independently Inhibit Tumor Necrosis Factor (TNF)-Induced Apoptosis, Also Independently Inhibit TNF-Induced Release of Arachidonic Acid," <i>Journal of Virology</i> , 70(8):4904-4913 (August 1996)
AK	Kurihara, et al., "Selectivity of a Replication-Competent Adenovirus for Human Breast Carcinoma Cells Expressing the MUC1 Antigen," <i>The Journal of Clinical Investigation</i> , 106(6):763-771 (September 2000)
AL	Kwong, et al., "Combination Therapy with Suicide and Cytokine Genes for Hepatic Metastases of Lung Cancer," <i>Chest</i> , 112(5):1332-1337 (November 1997)
AM	La Thangue, N., "DRTF1/E2F: An Expanding Family of Heterodimeric Transcription Factors Implicated in Cell-Cycle Control," <i>Trends in Biochemical Science</i> , 19:108-114 (March 1994)
AN	Lebedeva, et al., "Tumor Suppression and Therapy Sensitization of Localized and Metastatic Breast Cancer by Adenovirus p53," <i>Human Gene Therapy</i> , 12:763-772 (May 1, 2001)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
Ennist, et al.
FILING DATE
FEBRUARY 22, 2002

Group



(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Li, et al., "A Hepatocellular Carcinoma-specific Adenovirus Variant, CV890, Eliminates Distant Human Liver Tumors in Combination with Doxorubicin," <i>Cancer Research</i> , 61:6428-6436 (September 1, 2001)
AB	Li, et al., "Replication Competent Oncolytic Adenovirus for Colon Cancer Therapy," <i>Proceedings of the American Association for Cancer Research</i> , 43:858, abstract No. 4251 (March 2002)
AC	Limbach, et al., "Development of Adenovirus Serotype 35 as a Gene Transfer Vector," poster presented at <i>The 10th Annual Meeting of the European Society for Gene Therapy</i> , Antibes, France, October 13-16, 2002
AD	Liu, et al., "Optimised Oncolytic Herpes Simplex Virus for Cancer Treatment," Abstract No. Or33, presented at <i>The 10th Annual Meeting of the European Society for Gene Therapy</i> , Antibes, France, October 13-16, 2002
AE	Liu, et al., "Optimized Oncolytic Herpes Simplex Virus for Cancer Treatment," poster presented at the <i>10th Annual Meeting of the European Society for Gene Therapy</i> , Antibes, France, October 13-16, 2002
AF	Lorence, et al., "Systemic Therapy of Human Tumor Xenografts Using PV701, an Oncolytic Strain of Newcastle Disease Virus, in Combination with a Cytotoxic Drug Demonstrates at Least Additive Antitumor Responses," <i>Proceedings of the American Association for Cancer Research</i> , 43:1096, abstract No. 5428 (March 2002)
AG	Lyons, R., "Multiple Approaches to Treating Systemic Disease with Oncolytic Adenoviruses," <i>ASM Gene Therapy Conference</i> , February 28, 2003, Banff, Alberta CA; oral presentation presented February 28, 2003
AH	Mabjeesh, et al., "Gene Therapy of Prostate Cancer: Current and Future Directions," <i>Endocrine-Related Cancer</i> , 9:115-139 (June 2002)
AI	Mach, et al., "Cytokine-Secreting Tumor Cell Vaccines," <i>Current Opinion in Immunology</i> , 12:571-575 (October 2000)
AJ	McDevitt, et al., "Sequences Capable of Restoring poly(A) Site Function Define Two Distinct Downstream Elements," <i>The EMBO Journal</i> , 5(11):2907-2913 (1986)
AK	Medina, et al., "Adenovirus-Mediated Cytotoxicity of Chronic Lymphocytic Leukemia Cells," <i>Blood</i> , 94(10):3499-3508 (November 15, 1999)
AL	Morris, et al., "Therapy of Head and Neck Squamous Cell Carcinoma with an Oncolytic Adenovirus Expressing HSV-tk," <i>Molecular Therapy</i> , 1(1):56-62 (January 2000)
AM	Nelson, et al., "Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor Using Ex Vivo Gene Transfer as Vaccines for the Treatment of Genitourinary Malignancies," <i>Cancer Chemother. Pharmacol.</i> , 46(Suppl):S67-S72 (July 11, 2000)
AN	Nemunaitis, et al., "Selective Replication and Oncolysis in p53 Mutant Tumors with ONYX-015, an E1B-55kD Gene-Deleted Adenovirus, in Patients with Advanced Head and Neck Cancer: A Phase II Trial," <i>Cancer Research</i> , 60:6359-6366 (November 15, 2000)


EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
Ennist, et al.
FILING DATE
FEBRUARY 22, 2002

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Neuman, et al., "Structure and Partial Genomic Sequence of the Human E2F1 Gene," <i>Gene</i> , 173:163-169 (1996)
AB	Neuman, et al., "Transcription of the E2F-1 Gene is Rendered Cell Cycle Dependent by E2F DNA-Binding Sites Within its Promoter," <i>Molecular and Cellular Biology</i> , 14(10):6607-6615 (October 1994)
AC	Nishizaki, et al., "Synergistic Inhibition of Human Lung Cancer Cell Growth by Adenovirus-Mediated Wild-Type p53 Gene Transfer in Combination with Docetaxel and Radiation Therapeutics In Vitro and In Vivo," <i>Clinical Cancer Research</i> , 7:2887-2897 (September 2001)
AD	Oh, et al., "In Vivo and In Vitro Analyses of Myc for Differential Promoter Activities of the Human Telomerase (hTERT) Gene in Normal and Tumor Cells," <i>Biochemical and Biophysical Research Communications</i> , 263:361-365 (1999)
AE	Paielli, et al., "Evaluation of the Biodistribution, Persistence, Toxicity, and Potential of Germ-Line Transmission of a Replication-Competent Human Adenovirus Following Intraprostatic Administration in the Mouse," <i>Molecular Therapy</i> , 1(3):263-274 (March 2000)
AF	Pardoll, D., "Paracrine Cytokine Adjuvants in Cancer Immunotherapy," <i>Annu. Rev. Immunol.</i> , 13:399-415 (1995)
AG	Parker, et al., "Adenoviral-Mediated Gene Therapy with Ad5CMVp53 and Ad5CMVp21 in Combination with Standard Therapies in Human Breast Cancer Cell Lines," <i>Annals of Clinical & Laboratory Science</i> , 30(4):395-405 (October 2000)
AH	Parr, et al., "Tumor-selective Transgene Expression In Vivo Mediated by an E2F-responsive Adenoviral Vector," <i>Nature Medicine</i> , 3(10):1145-1149 (October 1997)
AI	Pecora, et al., "Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers," <i>Journal of Clinical Oncology</i> , 20(9):2251-2266 (May 1, 2002)
AJ	Peter, et al., "A Novel Attenuated Replication-Competent Adenovirus for Melanoma Therapy," Abstract No. P78, presented at <i>The 10th Annual Meeting of the European Society for Gene Therapy</i> , Antibes, France, October 13-16, 2002
AK	Poole, et al., "Activity, Function, and Gene Regulation of the Catalytic Subunit of Telomerase (hTERT)," <i>Gene</i> , 269:1-12 (May 2001)
AL	Porosnicu, et al., "Increased Efficiency of the Selectively Oncolytic Vesicular Stomatitis Virus by Genetic Manipulation with Expression of Suicide Genes," <i>Proceedings of the American Association for Cancer Research</i> , 43:1096-1097, abstract No. 5431 (March 2002),
AM	Powell, et al., "A Conditionally Replicative Adenovirus Driven by the Human Telomerase Promoter Provides Broad-Spectrum Anti-Tumor Activity," <i>Molecular Therapy</i> , 5(5):abstract No. 51 (May 2002)
AN	Prell, et al., "Tumor Necrosis Factor (-armed Defective p53-pathway Selective Replicating Adenovirus for Cancer Treatment," <i>Proceedings of the American Association for Cancer Research</i> , 43:1110, abstract No. 5500 (March 2002)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
Ennist, et al.
FILING DATE
FEBRUARY 22, 2002

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Ramachandra, et al., "Re-engineering Adenovirus Regulatory Pathways to Enhance Oncolytic Specificity and Efficacy," <i>Nature Biotechnology</i> , 19:1035-1041 (November 2001)
AB	Raschke, et al., "A Replication Competent Dual-ad Vector for Treatment of Prostate Cancer," Abstract No. Or41, presented at <i>The 10th Annual Meeting of the European Society for Gene Therapy</i> , Antibes, France, October 13-16, 2002
AC	Rassa, et al., "Molecular Basis for Naturally Occurring Elevated Readthrough Transcription Across the M-F Junction of the Paramyxovirus SV5," <i>Virology</i> , 247:274-286 (1998)
AD	Reddy, et al., "Development of Adenovirus Serotype 35 as a Gene Transfer Vector," <i>American Society of Gene Therapy 5th Annual Meeting</i> , June 5-9, 2002, poster presented June 6, 2002
AE	Reddy, et al., "Development of Adenovirus Serotype 35 as a Gene Transfer Vector," <i>American Society of Gene Therapy 5th Annual Meeting</i> , June 5-9, 2002, <i>Molecular Therapy</i> , 5(5):S67-S68, abstract No. 200
AF	Reszka, et al., "New Targeting System for High-efficient Delivery of Anti-neoplastic Drugs or Genes into the Angiogenetic Areas of Liver Tumors," <i>Proceedings of the American Association for Cancer Research</i> , 43:663, abstract No. 3289 (March 2002)
AG	Ries, et al., "ONYX-015: Mechanisms of Action and Clinical Potential of a Replication-Selective Adenovirus," <i>British Journal of Cancer</i> , 86:5-11 (January 7, 2002)
AH	Rodriguez, et al., "Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for Prostate-specific Antigen-positive Prostate Cancer Cells," <i>Cancer Research</i> , 57:2559-2563 (July 1, 1997)
AI	Russell, W., "Update on Adenovirus and Its Vectors," <i>Journal of General Virology</i> , 81:2573-2604 (November 2000)
AJ	Ryan, et al., "An Oncolytic Adenovirus Dependent on Two Prevalent Alterations in Human Cancer: Efficacy, Tolerability, and Tumor-Selectivity Following Systemic Administration," <i>Eleventh International Conference on Gene Therapy of Cancer</i> , San Diego, CA, December 12-14, 2002, 10(Suppl. 1):abstract No. 036
AK	Ryan, et al., "Anti-Tumor Efficacy and Preclinical Proof-of-Concept Following Systemic Administration of an Oncolytic Adenovirus Dependent Upon Two Prevalent Alterations in Human Cancer," Abstract No. Or34, presented at <i>The 10th Annual Meeting of the European Society for Gene Therapy</i> , Antibes, France, October 13-16, 2002
AL	Sanchez-Prieto, et al., "Lack of Correlation Between p53 Protein Level and Sensitivity to DNA-damaging Agents in Keratinocytes Carrying Adenovirus E1a Mutants," <i>Oncogene</i> , 11:675-682 (1995)
AM	Sauthoff, et al., "Deletion of the Adenoviral E1b-19kD Gene Enhances Tumor Cell Killing of a Replicating Adenoviral Vector," <i>Human Gene Therapy</i> , 11:379-388 (February 10, 2000)
AN	Sauthoff, et al., "p53 Expression Late in the Life Cycle of a Replication-competent Adenovirus Improves Tumor Cell Killing and Deletion of the Death Protein Improves Specificity," <i>Proceedings of the American Association for Cancer Research</i> , 43:1098, abstract No. 5439 (March 2002)

EXAMINER

DATE CONSIDERED


*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
Ennist, et al.
FILING DATE
FEBRUARY 22, 2002

Group



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Schwarz, et al., "Interactions of the p107 and Rb Proteins with E2F During the Cell Proliferation Response," <i>The EMBO Journal</i> , 12(3):1013-1020 (1993)
AB	Sellers, et al., "A Potent Transrepression Domain in the Retinoblastoma Protein Induces a Cell Cycle Arrest When Bound to E2F Sites," <i>Proc. Natl. Acad. Sci. USA</i> , 92:11544-11548 (December 1995)
AC	Shay, et al., "A Survey of Telomerase Activity in Human Cancer," <i>European Journal of Cancer</i> , 33(5):787-791 (1997)
AD	Shay, et al., "Telomerase and Cancer," <i>Human Molecular Genetics</i> , 10(7):677-685 (April 2001)
AE	Shi, et al., "Modulation of the Specificity and Activity of a Cellular Promoter in an Adenoviral Vector," <i>Human Gene Therapy</i> , 8:403-410 (March 1, 1997)
AF	Simons, et al., "Bioactivity of Autologous Irradiated Renal Cell Carcinoma Vaccines Generated by Ex Vivo Granulocyte-Macrophage Colony-stimulating Factor Gene Transfer," <i>Cancer Research</i> , 57:1537-1546 (April 15, 1997)
AG	Simons, et al., "Induction of Immunity to Prostate Cancer Antigens: Results of a Clinical Trial of Vaccination with Irradiated Autologous Prostate Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-stimulating Factor Using," <i>Cancer Research</i> , 59:5160-5168 (October 15, 1999)
AH	Soiffer, et al., "Vaccination with Irradiated Autologous Melanoma Cells Engineered to Secrete Human Granulocyte-Macrophage Colony-Stimulating Factor Generates Potent Antitumor Immunity in Patients with Metastatic Melanoma," <i>Proc. Natl. Acad. Sci. USA</i> , 95:13141-13146 (October 1998)
AI	Spitler, et al., "Adjuvant Therapy of Stage III and IV Malignant Melanoma Using Granulocyte-Macrophage Colony-Stimulating Factor," <i>Journal of Clinical Oncology</i> , 18(8):1614-1621 (April 2000)
AJ	Steinwaerder, et al., "Insulation from Viral Transcriptional Regulatory Elements Improves Inducible Transgene Expression from Adenovirus Vectors In Vitro and In Vivo," <i>Gene Therapy</i> , 7(7):556-567 (April 2000)
AK	Stewart, D., "Oncolytic Adenovirus Dependent on Two Prevalent Alterations in Human Cancer," oral presentation presented at the <i>Eleventh International Conference on Gene Therapy of Cancer</i> , San Diego, CA, December 12-14, 2002
AL	Stewart, et al., "OAV001, an Oncolytic Adenovirus Dependent on Rb-Pathway Alterations in Human Cancer," <i>American Society for Gene Therapy, 5th Annual Meeting</i> , June 5-9, 2002; oral presentation presented June 7, 2002
AM	Stewart, et al., "OAV001, an Oncolytic Adenovirus Dependent on Rb-Pathway Alterations in Human Cancer," <i>Molecular Therapy</i> , 5(5):abstract No. 53 (May 2002)
AN	Stewart, et al., "Telomerase and Human Tumorigenesis," <i>Seminars in Cancer Biology</i> , 10:399-406 (December 2000)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
Ennist, et al.
FILING DATE
FEBRUARY 22, 2002

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Strauss, et al., "Unrestricted Cell Cycling and Cancer," <i>Nature Medicine</i> , 1(12):1245-1246 (December 1995)
AB	Takahashi, et al., "Analysis of Promoter Binding by the E2F and pRB Families In Vivo: Distinct E2F Proteins Mediate Activation and Repression," <i>Genes & Development</i> , 14:804-816 (April 1, 2000)
AC	Takakura, et al., "Cloning of Human Telomerase Catalytic Subunit (hTERT) Gene Promoter and Identification of Proximal Core Promoter Sequences Essential for Transcriptional Activation in Immortalized and Cancer Cells," <i>Cancer Research</i> , 59:551-557 (February 1, 1999)
AD	Terhune, et al., "Regulation of Human Papillomavirus Type 31 Polyadenylation During the Differentiation-Dependent Life Cycle," <i>Journal of Virology</i> , 73(9):7185-7192 (September 1999)
AE	Tevosian, et al., "Expression of the E2F-1/DP-1 Transcription Factor in Murine Development," <i>Cell Growth and Differentiation</i> , 7:43-52 (January 1996)
AF	Tollefson, et al., "The Adenovirus Death Protein (E3-11.6K) Is Required at Very Late Stages of Infection for Efficient Cell Lysis and Release of Adenovirus from Infected Cells," <i>Journal of Virology</i> , 70(4):2296-2306 (April 1996)
AG	Tsukuda, et al., "An E2F-responsive Replication-selective Adenovirus Targeted to the Defective Cell Cycle in Cancer Cells: Potent Antitumoral Efficacy but No Toxicity to Normal Cells," <i>Cancer Research</i> , 62:3438-3447 (June 15, 2002)
AH	Tsuruta, et al., "Combination Effect of Adenovirus-Mediated Pro-Apoptotic bax Gene Transfer With Cisplatin or Paclitaxel Treatment in Ovarian Cancer Cell Lines," <i>European Journal of Cancer</i> , 37:531-541 (March 2001)
AI	Ueno, et al., "Chemosensitization of HER-2/neu-overexpressing Human Breast Cancer Cells to Paclitaxel (Taxol) by Adenovirus Type 5 E1A," <i>Oncogene</i> , 15:953-960 (1997)
AJ	Vassaux, et al., "Insulation of a Conditionally Expressed Transgene in an Adenoviral Vector," <i>Gene Therapy</i> , 6:1192-1197 (1999)
AK	Vile, et al., "The Oncolytic Virotherapy Treatment Platform for Cancer: Unique Biological and Biosafety Points to Consider," <i>Cancer Gene Therapy</i> , 9:1062-1067 (December 2002)
AL	Waehler, et al., "Experimental Gene Therapy of Hepatocellular Carcinoma: Expression of IL-12, 4-1BBL and IL-2 From a Single Adenoviral Vector," Abstract No. P33, presented at <i>The 10th Annual Meeting of the European Society for Gene Therapy</i> , Antibes, France, October 13-16, 2002
AM	Wahle, et al., "The Mechanism of 3' Cleavage and Polyadenylation of Eukaryotic Pre-MrnA," <i>Progress in Nucleic Acid Research and Molecular Biology</i> , 57:41-71 (1997)
AN	Weinberg, R., "The Retinoblastoma Protein and Cell Cycle Control," <i>Cell</i> , 81:323-330 (May 5, 1995)

EXAMINER

DATE CONSIDERED


*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31704A
APPLICATION NO.
10/081,969
APPLICANT
Ennist, et al.
FILING DATE
FEBRUARY 22, 2002

Group



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Wen, et al., "Effect of Viral Replication on Pharmacokinetics of 01/PEME, a Recombinant Oncolytic Adenovirus, in a Human Lung Cancer Xenograft Model," <i>Proceedings of the American Association for Cancer Research</i> , 43:1098, abstract No. 5440 (March 2002)
AB	Wold, et al., "Adenovirus Proteins that Subvert Host Defenses," <i>Trends in Microbiology</i> , 2(11):437-443 (November 1994)
AC	Wold, et al., "E3 Transcription Unit of Adenovirus," <i>Curr. Top. Microbiol. Immunol.</i> , 199:237-274 (1995)
AD	Wold, et al., "Immune Responses to Adenoviruses: Viral Evasion Mechanisms and Their Implications for the Clinic," <i>Current Opinion in Immunology</i> , 11:380-386 (1999)
AE	Wold, "Region E3 of Adenovirus: A Cassette of Genes Involved in Host Immunosurveillance and Virus-Cell Interactions," <i>Virology</i> , 184:1-8 (1991)
AF	Yu, et al., "Antitumor Synergy of CV787, a Prostate Cancer-specific Adenovirus, and Paclitaxel and Docetaxel," <i>Cancer Research</i> , 61:517-525 (January 15, 2001)
AG	Yu, et al., "Identification of the Transcriptional Regulatory Sequences of Human Kallikrein 2 and Their Use in the Construction of Calydon Virus 764, an Attenuated Replication Competent Adenovirus for Prostate Cancer Therapy," <i>Cancer Research</i> , 59:1498-1504 (April 1, 1999)
AH	Yu, et al., "The Addition of Adenovirus Type 5 Region E3 Enables Calydon Virus 787 to Eliminate Distant Prostate Tumor Xenografts," <i>Cancer Research</i> , 59:4200-4203 (September 1, 1999)
AI	Zhang, et al., "Ionizing Radiation Increases Adenovirus Entry into Cells and Improves Transgene Expression in Intrahepatic Colon Cancer Xenografts," <i>Proceedings of the American Association for Cancer Research</i> , 43:597, abstract No. 2955 (March 2002)
AJ	Zhou, et al., "E1A Sensitizes HER2/neu-overexpressing Ewing's Sarcoma Cells to Topoisomerase II-targeting Anticancer Drugs," <i>Cancer Research</i> , 61:3394-3398 (April 15, 2001)
AK	Zhu, et al., "In Vivo Spread of Oncolytic Adenoviruses in Xenograft Tumor Models," <i>Molecular Therapy</i> , 5(5):abstract No. 317 (May 2002)
AL	Zsengellér, et al., "Adenovirus-Mediated Granulocyte-Macrophage Colony-Stimulating Factor Improves Lung Pathology of Pulmonary Alveolar Proteinosis in Granulocyte-Macrophage Colony-Stimulating Factor-Deficient Mice," <i>Human Gene Therapy</i> , 9:2101-2109 (September 20, 1998)
AM	Zwicker, et al., "Cell Cycle-regulated Transcription in Mammalian Cells," <i>Progress in Cell Cycle Research</i> , 1:91-99 (1995)
AN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.